QUITE SIMPLY, THE ANTIHYPERTENSIVE AND LIPID-Lowering Treatment to Prevent
Heart Attack Trial (ALLHAT) is one of the most important trials of antihypertensive therapy.
For decades, experts have passionately debated which class of drugs should be initial
therapy for hypertension. Resolution of this issue, which has enormous clinical, public
health, and economic implications, comes at a time of intense pressure to reduce health
care costs while improving clinical outcomes. In this setting, the ALLHAT results, reported in …